OFI Invest Asset Management Purchases 501,185 Shares of Colgate-Palmolive Company $CL

OFI Invest Asset Management raised its position in shares of Colgate-Palmolive Company (NYSE:CL) by 35,047.9% in the fourth quarter, Holdings Channel reports. The fund owned 502,615 shares of the company’s stock after buying an additional 501,185 shares during the quarter. OFI Invest Asset Management’s holdings in Colgate-Palmolive were worth $39,717,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. Cache Advisors LLC bought a new stake in Colgate-Palmolive during the fourth quarter valued at about $523,000. Powers Advisory Group LLC boosted its holdings in Colgate-Palmolive by 3.1% during the fourth quarter. Powers Advisory Group LLC now owns 8,926 shares of the company’s stock valued at $705,000 after acquiring an additional 269 shares during the period. Woodmont Investment Counsel LLC boosted its holdings in Colgate-Palmolive by 7.4% during the fourth quarter. Woodmont Investment Counsel LLC now owns 3,707 shares of the company’s stock valued at $293,000 after acquiring an additional 257 shares during the period. Greenleaf Trust raised its position in shares of Colgate-Palmolive by 11.4% during the fourth quarter. Greenleaf Trust now owns 38,029 shares of the company’s stock valued at $3,005,000 after buying an additional 3,901 shares during the last quarter. Finally, Capital Advisors Ltd. LLC raised its position in shares of Colgate-Palmolive by 33.3% during the fourth quarter. Capital Advisors Ltd. LLC now owns 772 shares of the company’s stock valued at $61,000 after buying an additional 193 shares during the last quarter. 80.41% of the stock is currently owned by institutional investors.

Colgate-Palmolive Stock Performance

NYSE:CL opened at $85.54 on Thursday. Colgate-Palmolive Company has a 12-month low of $74.54 and a 12-month high of $99.33. The company has a quick ratio of 0.54, a current ratio of 0.83 and a debt-to-equity ratio of 18.82. The firm has a market capitalization of $68.63 billion, a PE ratio of 32.65, a price-to-earnings-growth ratio of 3.91 and a beta of 0.34. The firm has a 50-day moving average price of $91.04 and a 200 day moving average price of $83.52.

Colgate-Palmolive (NYSE:CL) last posted its quarterly earnings results on Friday, January 30th. The company reported $0.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.91 by $0.04. Colgate-Palmolive had a net margin of 10.45% and a return on equity of 353.72%. The firm had revenue of $5.23 billion during the quarter, compared to analyst estimates of $5.13 billion. During the same quarter in the prior year, the business posted $0.91 earnings per share. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. Research analysts anticipate that Colgate-Palmolive Company will post 3.75 earnings per share for the current fiscal year.

Colgate-Palmolive Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Monday, April 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 2.5%. This is a boost from Colgate-Palmolive’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Monday, April 20th. Colgate-Palmolive’s dividend payout ratio (DPR) is currently 79.39%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on CL shares. JPMorgan Chase & Co. upped their price objective on shares of Colgate-Palmolive from $93.00 to $97.00 and gave the company an “overweight” rating in a research report on Monday, February 2nd. Deutsche Bank Aktiengesellschaft raised shares of Colgate-Palmolive from a “hold” rating to a “buy” rating and upped their price objective for the company from $90.00 to $98.00 in a research report on Monday, March 30th. Evercore upped their price objective on shares of Colgate-Palmolive from $94.00 to $100.00 and gave the company an “outperform” rating in a research report on Monday, February 2nd. Argus reaffirmed a “hold” rating on shares of Colgate-Palmolive in a research report on Thursday, December 11th. Finally, Bank of America upped their price objective on shares of Colgate-Palmolive from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Monday, February 2nd. Eleven equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Colgate-Palmolive presently has a consensus rating of “Moderate Buy” and an average target price of $95.13.

Insider Buying and Selling at Colgate-Palmolive

In related news, CFO Stanley J. Sutula III sold 97,843 shares of the stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $94.27, for a total value of $9,223,659.61. Following the completion of the transaction, the chief financial officer owned 55,310 shares of the company’s stock, valued at $5,214,073.70. This represents a 63.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Panagiotis Tsourapas sold 35,000 shares of the stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $94.61, for a total transaction of $3,311,350.00. Following the completion of the transaction, the chief operating officer directly owned 10,415 shares of the company’s stock, valued at $985,363.15. This trade represents a 77.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 184,683 shares of company stock worth $17,486,693. 0.34% of the stock is currently owned by company insiders.

Key Headlines Impacting Colgate-Palmolive

Here are the key news stories impacting Colgate-Palmolive this week:

• Positive Sentiment: UBS trimmed its price target to $98 (from $100) but kept a Buy rating, signaling continued conviction in Colgate’s fundamentals and supporting demand among buy‑side investors. UBS lowers price target to $98 but keeps Buy
• Positive Sentiment: Colgate‑Palmolive was included on a list of best low‑volatility blue‑chip stocks, reinforcing its defensive/steady‑growth narrative (appealing to income and risk‑averse investors given CL’s low beta). InsiderMonkey low‑volatility list
• Positive Sentiment: Analysts’ consensus remains above neutral (reported as a “Moderate Buy”), which helps sustain investor confidence despite some target cuts. Consensus Moderate Buy report
• Neutral Sentiment: Piper Sandler lowered its target from $96 to $92 but maintained an Overweight rating — a mixed signal that trims upside expectations while still backing the stock. Piper Sandler cuts target to $92, keeps Overweight Benzinga
• Negative Sentiment: Wells Fargo cut its price target to $92 and moved to an Equal Weight rating — a clearer downside pressure on near‑term sentiment because it reduces the analyst‑driven upside case. Wells Fargo cuts target to $92, downgrades to EW

About Colgate-Palmolive

Colgate-Palmolive Company is a global consumer products company with a long history in household and personal care categories. The business traces its roots to the early 19th century and has evolved into a multinational manufacturer and marketer of everyday consumer goods focused on health, hygiene and home care.

The company’s core activities center on oral care, personal care, home care and pet nutrition. Its product portfolio includes toothpaste, toothbrushes and mouthwash in oral care; soaps, body washes and deodorants in personal care; dishwashing liquids, surface cleaners and other household products in home care; and scientifically formulated pet foods under its pet nutrition business.